{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T13:30:30Z","timestamp":1780061430505,"version":"3.54.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T00:00:00Z","timestamp":1494460800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s40272-017-0232-6","type":"journal-article","created":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T20:21:49Z","timestamp":1494534109000},"page":"303-311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Monogenic Periodic Fever Syndromes: Treatment Options for the Pediatric Patient"],"prefix":"10.1007","volume":"19","author":[{"given":"Seza","family":"Ozen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selcan","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,11]]},"reference":[{"key":"232_CR1","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev.immunol.25.022106.141627","volume":"27","author":"SL Masters","year":"2009","unstructured":"Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol. 2009;27:621\u201368.","journal-title":"Annu Rev Immunol."},{"issue":"1","key":"232_CR2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/ng0997-25","volume":"17","author":"FMFC French","year":"1997","unstructured":"French FMFC. A candidate gene for familial Mediterranean fever. Nat Genet. 1997;17(1):25\u201331.","journal-title":"Nat Genet."},{"key":"232_CR3","doi-asserted-by":"crossref","unstructured":"Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell. 1997;90(4):797\u2013807.","DOI":"10.1016\/S0092-8674(00)80539-5"},{"issue":"3","key":"232_CR4","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.semarthrit.2007.03.005","volume":"37","author":"Y Berkun","year":"2007","unstructured":"Berkun Y, Padeh S, Reichman B, Zaks N, Rabinovich E, Lidar M, et al. A single testing of serum amyloid a levels as a tool for diagnosis and treatment dilemmas in familial Mediterranean fever. Semin Arthritis Rheum. 2007;37(3):182\u20138.","journal-title":"Semin Arthritis Rheum."},{"key":"232_CR5","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/archinte.1961.03620040065007","volume":"107","author":"H Heller","year":"1961","unstructured":"Heller H, Sohar E, Gafni J, Heller J. Amyloidosis in familial Mediterranean fever. An independent genetically determined character. Arch Intern Med. 1961;107:539\u201350.","journal-title":"Arch Intern Med."},{"issue":"2","key":"232_CR6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.semarthrit.2010.11.003","volume":"41","author":"U Meinzer","year":"2011","unstructured":"Meinzer U, Quartier P, Alexandra JF, Hentgen V, Retornaz F, Kone-Paut I. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum. 2011;41(2):265\u201371.","journal-title":"Semin Arthritis Rheum."},{"issue":"3","key":"232_CR7","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3899\/jrheum.100718","volume":"38","author":"S Ozen","year":"2011","unstructured":"Ozen S, Bilginer Y, Aktay Ayaz N, Calguneri M. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol. 2011;38(3):516\u20138.","journal-title":"J Rheumatol."},{"issue":"3","key":"232_CR8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/ng756","volume":"29","author":"HM Hoffman","year":"2001","unstructured":"Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle\u2013Wells syndrome. Nat Genet. 2001;29(3):301\u20135.","journal-title":"Nat Genet."},{"issue":"4","key":"232_CR9","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/art.22491","volume":"56","author":"I Aksentijevich","year":"2007","unstructured":"Aksentijevich I, Putnam CD, Remmers EF, Mueller JL, Le J, Kolodner RD, et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum. 2007;56(4):1273\u201385.","journal-title":"Arthritis Rheum."},{"key":"232_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209686","author":"JB Kuemmerle-Deschner","year":"2016","unstructured":"Kuemmerle-Deschner JB, Ozen S, Kone-Paut I, Goldbach-Mansky R, Lachmann H, Blank N, et al. Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). Ann Rheum Dis. 2016. doi: 10.1136\/annrheumdis-2016-209686 .","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"232_CR11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0092-8674(00)80721-7","volume":"97","author":"MF McDermott","year":"1999","unstructured":"McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M, et al. Germline mutations in the extracellular domains of the 55\u00a0kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999;97(1):133\u201344.","journal-title":"Cell."},{"issue":"2","key":"232_CR12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1086\/321976","volume":"69","author":"I Aksentijevich","year":"2001","unstructured":"Aksentijevich I, Galon J, Soares M, Mansfield E, Hull K, Oh HH, et al. The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet. 2001;69(2):301\u201314.","journal-title":"Am J Hum Genet."},{"issue":"1","key":"232_CR13","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1086\/341357","volume":"71","author":"J Feldmann","year":"2002","unstructured":"Feldmann J, Prieur AM, Quartier P, Berquin P, Certain S, Cortis E, et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet. 2002;71(1):198\u2013203.","journal-title":"Am J Hum Genet."},{"issue":"2","key":"232_CR14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/9691","volume":"22","author":"SM Houten","year":"1999","unstructured":"Park YH, Wood G, Kastner DL, Chae JJ. Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol 2016;17(8):914-21.","journal-title":"Nat Genet."},{"issue":"6","key":"232_CR15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/MD.0b013e318190cfb7","volume":"87","author":"JC Hilst van der","year":"2008","unstructured":"van der Hilst JC, Bodar EJ, Barron KS, Frenkel J, Drenth JP, van der Meer JW, et al. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore). 2008;87(6):301\u201310.","journal-title":"Medicine (Baltimore)."},{"issue":"9","key":"232_CR16","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/annrheumdis-2015-207546","volume":"74","author":"NM Haar ter","year":"2015","unstructured":"ter Haar NM, Oswald M, Jeyaratnam J, Anton J, Barron KS, Brogan PA, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis. 2015;74(9):1636\u201344.","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"232_CR17","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/annrheumdis-2015-208690","volume":"75","author":"S Ozen","year":"2016","unstructured":"Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75(4):644\u201351.","journal-title":"Ann Rheum Dis."},{"key":"232_CR18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-med-061512-150641","volume":"65","author":"AA Jesus","year":"2014","unstructured":"Jesus AA, Goldbach-Mansky R. IL-1 blockade in autoinflammatory syndromes. Annu Rev Med. 2014;65:223\u201344.","journal-title":"Annu Rev Med."},{"issue":"25","key":"232_CR19","first-page":"1302","volume":"287","author":"SE Goldfinger","year":"1972","unstructured":"Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med. 1972;287(25):1302.","journal-title":"N Engl J Med."},{"issue":"6","key":"232_CR20","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.jpeds.2012.05.047","volume":"161","author":"S Padeh","year":"2012","unstructured":"Padeh S, Gerstein M, Berkun Y. Colchicine is a safe drug in children with familial Mediterranean fever. J Pediatr. 2012;161(6):1142\u20136.","journal-title":"J Pediatr."},{"issue":"3","key":"232_CR21","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/berh.2000.0089","volume":"14","author":"A Livneh","year":"2000","unstructured":"Livneh A, Langevitz P. Diagnostic and treatment concerns in familial Mediterranean fever. Baillieres Best Pract Res Clin Rheumatol. 2000;14(3):477\u201398.","journal-title":"Baillieres Best Pract Res Clin Rheumatol."},{"issue":"6","key":"232_CR22","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/qjmed\/92.6.309","volume":"92","author":"HA Majeed","year":"1999","unstructured":"Majeed HA, Rawashdeh M, El-Shanti H, Qubain H, Khuri-Bulos N, Shahin HM. Familial Mediterranean fever in children: the expanded clinical profile. QJM. 1999;92(6):309\u201318.","journal-title":"QJM."},{"issue":"8","key":"232_CR23","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/art.1780340806","volume":"34","author":"D Zemer","year":"1991","unstructured":"Zemer D, Livneh A, Danon YL, Pras M, Sohar E. Long-term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum. 1991;34(8):973\u20137.","journal-title":"Arthritis Rheum."},{"issue":"16","key":"232_CR24","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM198604173141601","volume":"314","author":"D Zemer","year":"1986","unstructured":"Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med. 1986;314(16):1001\u20135.","journal-title":"N Engl J Med."},{"issue":"10","key":"232_CR25","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1136\/annrheumdis-2011-201271","volume":"71","author":"Y Shinar","year":"2012","unstructured":"Shinar Y, Obici L, Aksentijevich I, Bennetts B, Austrup F, Ceccherini I, et al. Guidelines for the genetic diagnosis of hereditary recurrent fevers. Ann Rheum Dis. 2012;71(10):1599\u2013605.","journal-title":"Ann Rheum Dis."},{"issue":"2","key":"232_CR26","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/ard.60.2.146","volume":"60","author":"E Ben-Chetrit","year":"2001","unstructured":"Ben-Chetrit E, Backenroth R. Amyloidosis induced, end stage renal disease in patients with familial Mediterranean fever is highly associated with point mutations in the MEFV gene. Ann Rheum Dis. 2001;60(2):146\u20139.","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"232_CR27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2174\/1568010053622984","volume":"4","author":"C Cerquaglia","year":"2005","unstructured":"Cerquaglia C, Diaco M, Nucera G, La Regina M, Montalto M, Manna R. Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update. Curr Drug Targets Inflamm Allergy. 2005;4(1):117\u201324.","journal-title":"Curr Drug Targets Inflamm Allergy."},{"issue":"8","key":"232_CR28","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nri3261","volume":"12","author":"H Park","year":"2012","unstructured":"Park H, Bourla AB, Kastner DL, Colbert RA, Siegel RM. Lighting the fires within: the cell biology of autoinflammatory diseases. Nat Rev Immunol. 2012;12(8):570\u201380.","journal-title":"Nat Rev Immunol."},{"issue":"1","key":"232_CR29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/clpt.2013.148","volume":"95","author":"I Grattagliano","year":"2014","unstructured":"Grattagliano I, Bonfrate L, Ruggiero V, Scaccianoce G, Palasciano G, Portincasa P. Novel therapeutics for the treatment of familial Mediterranean fever: from colchicine to biologics. Clin Pharmacol Ther. 2014;95(1):89\u201397.","journal-title":"Clin Pharmacol Ther."},{"key":"232_CR30","first-page":"75","volume":"10","author":"J Hilst van der","year":"2016","unstructured":"van der Hilst J, Moutschen M, Messiaen PE, Lauwerys BR, Vanderschueren S. Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. Biologics. 2016;10:75\u201380.","journal-title":"Biologics."},{"issue":"8","key":"232_CR31","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/0003-4819-157-8-201210160-00003","volume":"157","author":"PJ Hashkes","year":"2012","unstructured":"Hashkes PJ, Spalding SJ, Giannini EH, Huang B, Johnson A, Park G, et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med. 2012;157(8):533\u201341.","journal-title":"Ann Intern Med."},{"issue":"4","key":"232_CR32","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00467-015-3249-5","volume":"31","author":"R Topaloglu","year":"2016","unstructured":"Topaloglu R, Batu ED, Orhan D, Ozen S, Besbas N. Anti-interleukin 1 treatment in secondary amyloidosis associated with autoinflammatory diseases. Pediatr Nephrol. 2016;31(4):633\u201340.","journal-title":"Pediatr Nephrol."},{"issue":"suppl 2","key":"232_CR33","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1136\/annrheumdis-2016-eular.3881","volume":"75","author":"FD Benedetti","year":"2016","unstructured":"Benedetti FD, Anton J, Gattorno M, Lachmann H, Kone-Paut I, Ozen S. A phase III pivotal umbrella trial of canakinumab in patients with autoinflammatory periodic fever syndromes (colchicine resistant FMF, HIDS\/MKD and TRAPS). Ann Rheum Dis. 2016;75(suppl 2):615\u20136.","journal-title":"Ann Rheum Dis."},{"issue":"5 Suppl 42","key":"232_CR34","first-page":"S99","volume":"24","author":"E Seyahi","year":"2006","unstructured":"Seyahi E, Ozdogan H, Celik S, Ugurlu S, Yazici H. Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents. Clin Exp Rheumatol. 2006;24(5 Suppl 42):S99\u2013103.","journal-title":"Clin Exp Rheumatol."},{"issue":"7","key":"232_CR35","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/RHU.0b013e31823682f5","volume":"17","author":"SA Bilgen","year":"2011","unstructured":"Bilgen SA, Kilic L, Akdogan A, Kiraz S, Kalyoncu U, Karadag O, et al. Effects of anti-tumor necrosis factor agents for familial mediterranean fever patients with chronic arthritis and\/or sacroiliitis who were resistant to colchicine treatment. J Clin Rheumatol. 2011;17(7):358\u201362.","journal-title":"J Clin Rheumatol."},{"issue":"5","key":"232_CR36","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1136\/annrheumdis-2011-201268","volume":"72","author":"N Haar Ter","year":"2013","unstructured":"Ter Haar N, Lachmann H, Ozen S, Woo P, Uziel Y, Modesto C, et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis. 2013;72(5):678\u201385.","journal-title":"Ann Rheum Dis."},{"issue":"7","key":"232_CR37","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3109\/00016489.2012.656321","volume":"132","author":"A Koitschev","year":"2012","unstructured":"Koitschev A, Gramlich K, Hansmann S, Benseler S, Plontke SK, Koitschev C, et al. Progressive familial hearing loss in Muckle\u2013Wells syndrome. Acta Otolaryngol. 2012;132(7):756\u201362.","journal-title":"Acta Otolaryngol."},{"issue":"3","key":"232_CR38","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/art.37810","volume":"65","author":"JB Kuemmerle-Deschner","year":"2013","unstructured":"Kuemmerle-Deschner JB, Koitschev A, Ummenhofer K, Hansmann S, Plontke SK, Koitschev C, et al. Hearing loss in Muckle\u2013Wells syndrome. Arthritis Rheum. 2013;65(3):824\u201331.","journal-title":"Arthritis Rheum."},{"issue":"1","key":"232_CR39","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.25057","volume":"62","author":"B Neven","year":"2010","unstructured":"Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V, et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease\/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 2010;62(1):258\u201367.","journal-title":"Arthritis Rheum."},{"issue":"7","key":"232_CR40","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/art.34409","volume":"64","author":"CH Sibley","year":"2012","unstructured":"Sibley CH, Plass N, Snow J, Wiggs EA, Brewer CC, King KA, et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum. 2012;64(7):2375\u201386.","journal-title":"Arthritis Rheum."},{"issue":"6","key":"232_CR41","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJMoa055137","volume":"355","author":"R Goldbach-Mansky","year":"2006","unstructured":"Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med. 2006;355(6):581\u201392.","journal-title":"N Engl J Med."},{"issue":"1","key":"232_CR42","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2310\/7750.2008.07050","volume":"12","author":"JB Ross","year":"2008","unstructured":"Ross JB, Finlayson LA, Klotz PJ, Langley RG, Gaudet R, Thompson K, et al. Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up. J Cutan Med Surg. 2008;12(1):8\u201316.","journal-title":"J Cutan Med Surg."},{"issue":"9","key":"232_CR43","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1136\/annrheumdis-2013-204877","volume":"74","author":"CH Sibley","year":"2015","unstructured":"Sibley CH, Chioato A, Felix S, Colin L, Chakraborty A, Plass N, et al. A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease. Ann Rheum Dis. 2015;74(9):1714\u20139.","journal-title":"Ann Rheum Dis."},{"key":"232_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/art.40055","author":"J Rodriguez-Smith","year":"2017","unstructured":"Rodriguez-Smith J, Lin YC, Li Tsai W, Kim H, Montealegre-Sanchez G, Chapelle D, et al. CSF cytokines correlate with aseptic meningitis and blood brain barrier function in neonatal-onset multisystem inflammatory disease (NOMID). Arthritis Rheumatol. 2017. doi: 10.1002\/art.40055 .","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"232_CR45","doi-asserted-by":"crossref","first-page":"R202","DOI":"10.1186\/ar3535","volume":"13","author":"I Kone-Paut","year":"2011","unstructured":"Kone-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, Hachulla E, Leslie KS, Mouy R, et al. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther. 2011;13(6):R202.","journal-title":"Arthritis Res Ther."},{"issue":"23","key":"232_CR46","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","volume":"360","author":"HJ Lachmann","year":"2009","unstructured":"Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360(23):2416\u201325.","journal-title":"N Engl J Med."},{"issue":"12","key":"232_CR47","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1136\/ard.2011.152728","volume":"70","author":"JB Kuemmerle-Deschner","year":"2011","unstructured":"Kuemmerle-Deschner JB, Hachulla E, Cartwright R, Hawkins PN, Tran TA, Bader-Meunier B, et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis. 2011;70(12):2095\u2013102.","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"232_CR48","doi-asserted-by":"crossref","first-page":"R34","DOI":"10.1186\/ar3266","volume":"13","author":"JB Kuemmerle-Deschner","year":"2011","unstructured":"Kuemmerle-Deschner JB, Ramos E, Blank N, Roesler J, Felix SD, Jung T, et al. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1beta mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). Arthritis Res Ther. 2011;13(1):R34.","journal-title":"Arthritis Res Ther."},{"issue":"4","key":"232_CR49","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/rheumatology\/kev416","volume":"55","author":"JB Kuemmerle-Deschner","year":"2016","unstructured":"Kuemmerle-Deschner JB, Hofer F, Endres T, Kortus-Goetze B, Blank N, Weissbarth-Riedel E, et al. Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome. Rheumatology (Oxford). 2016;55(4):689\u201396.","journal-title":"Rheumatology (Oxford)."},{"key":"232_CR50","unstructured":"Yokota S, Imagawa T, Nishikomori R, Takada H, Abrams K, Lheritier K, et al. Long-term safety and efficacy of canakinumab in cryopyrin-associated periodic syndrome: results from an open-label, phase III pivotal study in Japanese patients. Clin Exp Rheumatol. 2016 [Epub ahead of print, PMID 27974104]."},{"issue":"8","key":"232_CR51","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1002\/art.23687","volume":"58","author":"HM Hoffman","year":"2008","unstructured":"Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 2008;58(8):2443\u201352.","journal-title":"Arthritis Rheum."},{"issue":"10","key":"232_CR52","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.clinthera.2012.09.009","volume":"34","author":"HM Hoffman","year":"2012","unstructured":"Hoffman HM, Throne ML, Amar NJ, Cartwright RC, Kivitz AJ, Soo Y, et al. Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther. 2012;34(10):2091\u2013103.","journal-title":"Clin Ther."},{"issue":"3","key":"232_CR53","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrrheum.2013.174","volume":"10","author":"S Ozen","year":"2014","unstructured":"Ozen S, Bilginer Y. A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin. Nat Rev Rheumatol. 2014;10(3):135\u201347.","journal-title":"Nat Rev Rheumatol."},{"issue":"3","key":"232_CR54","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/art.33416","volume":"64","author":"AC Bulua","year":"2012","unstructured":"Bulua AC, Mogul DB, Aksentijevich I, Singh H, He DY, Muenz LR, et al. Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis Rheum. 2012;64(3):908\u201313.","journal-title":"Arthritis Rheum."},{"issue":"2","key":"232_CR55","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/art.24294","volume":"60","author":"B Nedjai","year":"2009","unstructured":"Nedjai B, Hitman GA, Quillinan N, Coughlan RJ, Church L, McDermott MF, et al. Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 2009;60(2):619\u201325.","journal-title":"Arthritis Rheum."},{"issue":"5","key":"232_CR56","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1002\/art.23475","volume":"58","author":"M Gattorno","year":"2008","unstructured":"Gattorno M, Pelagatti MA, Meini A, Obici L, Barcellona R, Federici S, et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 2008;58(5):1516\u201320.","journal-title":"Arthritis Rheum."},{"issue":"1","key":"232_CR57","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/annrheumdis-2015-209031","volume":"76","author":"M Gattorno","year":"2017","unstructured":"Gattorno M, Obici L, Cattalini M, Tormey V, Abrams K, Davis N, et al. Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study. Ann Rheum Dis. 2017;76(1):173\u20138.","journal-title":"Ann Rheum Dis."},{"issue":"9","key":"232_CR58","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1136\/ard.2010.144279","volume":"70","author":"N Quillinan","year":"2011","unstructured":"Quillinan N, Mannion G, Mohammad A, Coughlan R, Dickie LJ, McDermott MF, et al. Failure of sustained response to etanercept and refractoriness to anakinra in patients with T50M TNF-receptor-associated periodic syndrome. Ann Rheum Dis. 2011;70(9):1692\u20133.","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"232_CR59","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1136\/annrheumdis-2016-209335","volume":"76","author":"R Torene","year":"2017","unstructured":"Torene R, Nirmala N, Obici L, Cattalini M, Tormey V, Caorsi R, et al. Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome. Ann Rheum Dis. 2017;76(1):303\u20139.","journal-title":"Ann Rheum Dis."},{"issue":"4","key":"232_CR60","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/art.30215","volume":"63","author":"PM Vaitla","year":"2011","unstructured":"Vaitla PM, Radford PM, Tighe PJ, Powell RJ, McDermott EM, Todd I, et al. Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum. 2011;63(4):1151\u20135.","journal-title":"Arthritis Rheum."},{"issue":"1","key":"232_CR61","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5152\/eurjrheumatol.2014.14053","volume":"2","author":"N Akasbi","year":"2015","unstructured":"Akasbi N, Soyfoo MS. Successful treatment of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) with tocilizumab: a case report. Eur J Rheumatol. 2015;2(1):35\u20136.","journal-title":"Eur J Rheumatol."},{"issue":"16","key":"232_CR62","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.2169\/internalmedicine.54.3371","volume":"54","author":"T Hosoya","year":"2015","unstructured":"Hosoya T, Mizoguchi F, Hasegawa H, Miura K, Koike R, Kubota T, et al. A case presenting with the clinical characteristics of tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) without TNFRSF1A mutations successfully treated with tocilizumab. Intern Med. 2015;54(16):2069\u201372.","journal-title":"Intern Med."},{"issue":"5","key":"232_CR63","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.clpt.2004.01.012","volume":"75","author":"A Simon","year":"2004","unstructured":"Simon A, Drewe E, van der Meer JW, Powell RJ, Kelley RI, Stalenhoef AF, et al. Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther. 2004;75(5):476\u201383.","journal-title":"Clin Pharmacol Ther."},{"key":"232_CR64","doi-asserted-by":"crossref","first-page":"939847","DOI":"10.1155\/2013\/939847","volume":"2013","author":"A Vitale","year":"2013","unstructured":"Vitale A, Rigante D, Lucherini OM, Caso F, Muscari I, Magnotti F, et al. Biological treatments: new weapons in the management of monogenic autoinflammatory disorders. Mediators Inflamm. 2013;2013:939847.","journal-title":"Mediators Inflamm."},{"issue":"7","key":"232_CR65","first-page":"260","volume":"63","author":"EJ Bodar","year":"2005","unstructured":"Bodar EJ, van der Hilst JC, Drenth JP, van der Meer JW, Simon A. Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth J Med. 2005;63(7):260\u20134.","journal-title":"Neth J Med."},{"issue":"6","key":"232_CR66","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00431-015-2505-9","volume":"174","author":"S Kostjukovits","year":"2015","unstructured":"Kostjukovits S, Kalliokoski L, Antila K, Korppi M. Treatment of hyperimmunoglobulinemia D syndrome with biologics in children: review of the literature and Finnish experience. Eur J Pediatr. 2015;174(6):707\u201314.","journal-title":"Eur J Pediatr."},{"issue":"10","key":"232_CR67","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1093\/rheumatology\/kes097","volume":"51","author":"C Galeotti","year":"2012","unstructured":"Galeotti C, Meinzer U, Quartier P, Rossi-Semerano L, Bader-Meunier B, Pillet P, et al. Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency. Rheumatology (Oxford). 2012;51(10):1855\u20139.","journal-title":"Rheumatology (Oxford)."},{"issue":"2","key":"232_CR68","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/01.RHU.0000442576.41537.de","volume":"20","author":"HM Shendi","year":"2014","unstructured":"Shendi HM, Devlin LA, Edgar JD. Interleukin 6 blockade for hyperimmunoglobulin D and periodic fever syndrome. J Clin Rheumatol. 2014;20(2):103\u20135.","journal-title":"J Clin Rheumatol."},{"issue":"13","key":"232_CR69","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJMc072018","volume":"357","author":"PD Arkwright","year":"2007","unstructured":"Arkwright PD, Abinun M, Cant AJ. Mevalonic aciduria cured by bone marrow transplantation. N Engl J Med. 2007;357(13):1350.","journal-title":"N Engl J Med."},{"issue":"26","key":"232_CR70","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1056\/NEJMoa070715","volume":"356","author":"B Neven","year":"2007","unstructured":"Neven B, Valayannopoulos V, Quartier P, Blanche S, Prieur AM, Debre M, et al. Allogeneic bone marrow transplantation in mevalonic aciduria. N Engl J Med. 2007;356(26):2700\u20133.","journal-title":"N Engl J Med."},{"issue":"6","key":"232_CR71","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1111\/j.1600-6143.2011.03989.x","volume":"12","author":"S Chaudhury","year":"2012","unstructured":"Chaudhury S, Hormaza L, Mohammad S, Lokar J, Ekong U, Alonso EM, et al. Liver transplantation followed by allogeneic hematopoietic stem cell transplantation for atypical mevalonic aciduria. Am J Transplant. 2012;12(6):1627\u201331.","journal-title":"Am J Transplant."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-017-0232-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-017-0232-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-017-0232-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T13:08:14Z","timestamp":1750252094000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-017-0232-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,11]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["232"],"URL":"https:\/\/doi.org\/10.1007\/s40272-017-0232-6","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,11]]}}}